Impact of nicotine replacement therapy on smoking behavior

Annual Review of Public Health

Volumn 26, Issue , 2005, Pages 583-599

  Cummings, K Michael ^a   Hyland, Andrew ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

NRT; Pharmacotherapy; Smoking cessation; Tobacco

Indexed keywords

NICOTINE GUM; PLACEBO;

DRUG COST; DRUG EFFICACY; DRUG SAFETY; INHALER; LOZENGE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO; TRANSDERMAL PATCH;

CHEMISTRY, PHARMACEUTICAL; COMMUNITY HEALTH PLANNING; DRUG APPROVAL; DRUG COSTS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; HUMANS; LICENSURE, PHARMACY; NICOTINE; NICOTINIC AGONISTS; PATIENT ACCEPTANCE OF HEALTH CARE; PUBLIC HEALTH; SAFETY; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 17444375229     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.26.021304.144501     Document Type: Review

References (100)

1. Backlog for Quitline. 2001. Stop Mag. 3:6
2. Baldiner B, Hasenfratz M, Battig K. 1995. Switching to ultra-low nicotine cigarettes: effects of different tar yields and blocking of olfactory cues. Pharmacol. Biochem. Behav. 50:233-39
3. Bansal M, Cummings KM, Hyland A, Giovino G. 2004. Stop smoking medications: Who uses them? Who misuses them? Who is misinformed? Nicotine Tob. Res. In press
4. Behm FM, Schur C, Levin ED, Tashkin DP, Rose JE. 1993. Clinical evaluation of a citric acid inhaler for smoking cessation. Drug Alcohol Depend. 31:131-38
5. Benowitz NL. 1988. Pharmacologic aspects of cigarette smoking and nicotine addiction. N. Engl. J. Med. 319:1318-30
6. Benowitz NL. 1993. Nicotine replacement therapy. What has been accomplished - can we do better? Drugs 45:157-70
7. Benowitz NL. 1998. Nicotine Safety and Toxicity. New York: Oxford Univ. Press
8. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. 2003. Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior. Nicotine Tob. Res. 5:111-16
9. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. 2000. Smoking reduction with oral nicotine inhalers: double-blind, randomized clinical trial of efficacy and safety. BMJ 321:329-33
10. Deleted in proof
11. Boyle RG, Solberg LI, Magnan S, Davison G, Alesci NL. 2002. Does insurance coverage for drug therapy affect smoking cessation? Health Track. Nov./Dec.:162-68
12. Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE. 2001. Individual differences in smoking reward from denicotinized cigarettes. Nicotine Tob. Res. 3:101-9
13. Breese CR, Marks MJ, Logel J, Adams CE, Sullivan B, et al. 1997. Effect of smoking history on [3H] nicotine binding in human postmortem brain. J. Pharmacol. Exp. Ther. 282:7-13
14. Butschky MF, Bailey D, Henningfield JE, Pickworth WB. 1995. Smoking without nicotine delivery decreases withdrawal in 12-hour abstinence smokers. Pharmacol. Biochem. Behav. 50:91-96
15. Carperter M, Hughes JR, Solomon LJ, Callas PW. 2004. Both smoking reduction and motivational advice increase future cessation among smokers not currently planning to quit. J. Consult. Clin. Psychol. 72(3):371-81
16. Cent. Dis. Control Prev. 2001. Cigarette smoking among adults - United States, 1999. MMWR 50:869-73
17. Cent. Dis. Control Prev. 2002. Use of FDA-approved pharmacologic treatments for tobacco dependence - United States, 1984-1998. MMWR 49:665-68
18. Cryan JF, Gasparini F, Van Heeke G, Markowu A. 2002. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond buproprion. Drug Discovery Today 8:1025-34
19. Cummings KM. 2002. In debate: Can capitalism advance the goals of tobacco control? Addiction 97:957-62
20. Cummings KM. 2002. Programs and policies to discourage the use of tobacco products. Oncogene 21:7349-64
21. Cummings KM, Biernbaum RM, Zevon MA, Deloughry T, Jaen CR. 1994. Use and effectiveness of transdermal nicotine in primary care settings. Arch. Fam. Med. 3:682-89
22. Cummings KM, Hyland A, Giovino GA, Hastrup JL, Bauer JE, Bansal MA. 2004. Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine Tob. Res. In press
23. Cummings KM, Hyland A, Ockene JK, Hymowitz N, Manley M. 1997. Use of the nicotine skin patch by smokers in 20 U.S. communities, 1992-1993. Tob. Control 6(Suppl. 2):S63-70
24. Curry SJ, Grothaus LC, McAfee T, Pabiniak C. 1998. Use and cost effectiveness smoking-cessation services under four insurance plans in a health maintenance organization. N. Engl. J. Med. 339:673-79
25. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. 1995. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 274:1353-58
26. Dijkstra A, De Vries H. 2000. Subtypes of precontemplating smokers defined by different long-term plans to change their smoking behavior. Health Educ. Res. 15:423-34
27. Dunn WL Jr. 1972. Motives and Incentives in Cigarettes. Richmond, VA: Philip Morris Res. Cent.
28. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. 2002. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J. Clin. Psychopharmacol. 22:487-95
29. Etter JF, Perneger TV. 2001. Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public. Clin. Pharmacol. Ther. 69:175-83
30. Farkas AJ. 1999. When does cigarette fading increase the likelihood of future cessation? Ann. Behav. Med. 21:71-76
31. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. 2000. Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: US Dep. Health Hum. Serv., Public Health Serv.
32. Fiore MC, Hatsukami DK, Baker T. 2002. Effective tobacco dependence treatment. JAMA 288:1768-70
33. Fiore MC, Novotny TE, Pierce JP, Giovino GA, Hatziandreu EJ, Newcomb PA, et al. 1990. Methods used to quit smoking in the United States. Do cessation programs help? JAMA 263:2760-65
34. Fiore MC, Thompson SA, Lawrence DL, Welsch S, Andrews K, Ziamik M, et al. 2000. Helping Wisconsin women quit smoking: a successful collaboration. Wisc. Med. J. April:68-72
35. Foulds J, Ramstrom L, Burke M, Fagerström K. 2003. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob. Control 12:349-59
36. Freedman AM. 1995. Philip Morris memo likens nicotine to drugs. Wall Street J. Dec. 8
37. George TO, O'Malley SS. 2004. Current pharmacological treatments for nicotine dependence. Trends Pharmacol. Sci. 25:42-48
38. Giardina TD, Hyland A, Bauer UE, Higbee C, Cummings KM. 2004. Which population-based interventions would motivate smokers to think seriously about stopping smoking? Am. J. Health Prom. 18:405-8
39. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. 1994. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. BMJ 309:842-46
40. Halpin Schauffler H, Barker DC, Orleans TC. 2001. Medicaid coverage for tobacco dependence treatments. Health Aff. 20:298-303
41. Henningfield JE, Cohen C, Pickworth WD. 1993. Psychopharmacology of nicotine. In Nicotine Addiction. Principles and Management, ed. CT Orleans, J Slade, pp. 24-45. New York: Oxford Univ. Press
42. Herrera N, Franco R, Herrera L, Partidas A, Roland R, Fagerstrom KO. 1995. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 108:447-51
43. Hieda Y, Keyler DE, VanDeVoort JT, Niedbala RS, Raphael DE, et al. 1999. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 143:150-57
44. Howell TM, Sweeney WR. 1998. Aerosol and a method and apparatus for generating an aerosol. Philip Morris Inc. Patent: US5743251, April 28
45. Hu T, Sung HY, Keeler TE, Marciniak M. 2000. Cigarette consumption and sales of nicotine replacement products. Tob. Control 9(Suppl. 2):S60-63
46. Hughes JR. Four beliefs that may impede progress in the treatment of smoking. Tob. Control 8:323-26
47. Hughes JR, Cummings KM, Hyland A. 1999. Ability of smokers to reduce their smoking and its association with future smoking cessation. Addiction 94:109-14
48. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. 1999. Recent advances in the pharmacotherapy of smoking. JAMA 281:72-76
49. Deleted in proof
50. Hughes JR, Shiffman S, Callas P, Zhang J. 2003. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob. Control 12:21-27
51. Hurt RD, Robertson CR. 1998. Prying open the door to the cigarette industry's secrets about nicotine - the Minnesota Tobacco Trial. JAMA 280:1173-81
52. Hyland A, Levy D, Rezaishiraz H, Hughes J, Bauer JE, et al. 2005. Reduction in amount smoked predicts future cessation. Psychol. Addict. Behav. In press
53. Deleted in proof
54. Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, et al. 2004. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:83-90
55. Jorensby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, et al. 1999. A controlled trial of sustained release buproprion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340:685-91
56. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. 1994. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 271:589-94
57. Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terza JV. 2001. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob. Control 10:201-3
58. MacLeod ZR, Charles MA, Arnaldi VC, Adams IM. 2003. Telephone counseling as an adjunct to nicotine patches in smoking cessation. A randomized controlled trial. Med. J. Aust. 179:349-52
59. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, et al. 1992. Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 43:779-84
60. Marks MJ, Burch JB, Collins AC. 1983. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol. Exp. Ther. 226:817-25
61. McNeill A. 2004. Harm reduction. BMJ 328:885-87
62. Deleted in proof
63. Park CR, Munday DL. 2002. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int. J. Pharm. 237:215-26
64. Paul CL, Walsh RA, Girgis A. 2003. Nicotine replacement therapy products over the counter: real-life use in the Australian community. Aust. N. Z. J. Public Health 27:491-95
65. Pauly JL, Streck RJ, Cummings KM. 1995. US patents shed light on Eclipse and future cigarettes. Tob. Control 4:261-65
66. Perkins KA. 2001. Smoking cessation in women. Special considerations. CNS Drugs 15:391-411
67. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. 1997. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390:401-4
68. Pierce JP, Gilpin E, Farkas AJ. 1995. Nicotine patch use in the general population: results from the 1993 California Tobacco Survey. J. Natl. Cancer Inst. 87:87-93
69. Pierce JP, Gilpin EA. 2002. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 288:1260-64
70. Pinney JM, Henningfield JE, Shiffman S. 2002. Two-stage transmucosal medicine delivery system for symptom relief. Pinney Assoc. Patent: US6358060, March 19
71. Pontieri FE, Tanda G, Orzi F, Di Chiara G. 1996. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255-57
72. Richmond R, Zwar N. 2003. Review of bupropion for smoking cessation. Drug Alcohol Rev. 22:203-20
73. Role LW, Berg DK. 1996. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16:1077-85
74. Rose JE, Behm FM. 1995. There is more to smoking than the CNS effects of nicotine. In Effects of Nicotine on Biological Systems II, ed. PBS Clark, pp. 9-16. Basel: Burkhäuser Verlag
75. Rose JE, Behm FM, Levin ED. 1993. The role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol. Biochem. Behav. 44:891-900
76. Rose JE, Levin ED. 1991. Interrelationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br. J. Addict. 86:606-9
77. Schauffler HH, McMenammin S, Olson K, Boyce-Smith G, Rideout JA, Kamil J. 2001. Variations in treatment benefits influence smoking cessation: results of a randomized controlled trial. Tob. Control 10:175-80
78. Schuh KJ, Schuh LM, Henningfield JE. 1997. Nicotine nasal spray and vapor inhaler. Abuse liability assessment. Psychopharmacology 130:352-61
79. Seller EM, Kaplan HL, Tyndale RF. 2000. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin. Pharmacol. Ther. 68:35-43
80. Shiffman S, Fant RV, Gitchell JG. 2003. Nicotine delivery systems: How far has technology come? Am. J. Drug Deliv. 1:112-24
81. Shiffman S, Gitchell J, Pinney JM. 1997. Public health benefit of over-the-counter nicotine medications. Tob. Control 6:306-10
82. Shiffman S, Hughes JR, DiMarino ME, Sweeney CT. 2003. Patterns of over-the-counter nicotine gum use: persistent use and concurrent smoking. Addiction 98:1747-53
83. Deleted in proof
84. Shiffman SA, Paty JA, Rohay JM, Di-Marino ME, Gitchell JG. 2001. The efficacy of computer-tailored smoking cessation material as a supplement to nicotine patch therapy. Drug Alcohol Depend. 64:35-46
85. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. 2002. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 4:CD000146
86. Solomon LJ, Scharoun GM, Flynn BS, Seeker-Walker RH, Sepinwall D. 2000. Free nicotine patches plus proactive telephone peer support to help low-income women stop smoking. Prev. Med. 31:68-74
87. Stratton K, Shetty P, Wallace R, Bondurant S, eds. 2001. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: Natl. Acad. Press
88. Sweanor D. 2000. Regulatory imbalance between medicinal and non-medicinal nicotine. Addiction 95(Suppl.):S25-28
89. Thompson S. 2002. The nicotine vaccine. Stop Mag. 9:26-27
90. Thorndike A, Biener L, Rigotti NA. 2002. The impact on smoking cessation of switching nicotine replacement therapy to over-the-counter status. Am. J. Public Health 92:437-42
91. US Dep. Health Hum. Serv. 1988. The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General. Rockville, MD: US Dep. Health Hum. Serv., Cent. Dis. Control, Off. Smok. Health
92. US Dep. Health Hum. Serv. 2000. Reducing Tobacco Use: A Report of the Surgeon General. Rockville, MD: U.S. Dep. Health Hum. Serv., Public Health Serv., Cent. Dis. Control Prev., Natl. Cent. Chronic Dis. Prev. Health Promot., Off. Smok. Health
93. Warner KE, Slade J, Sweanor DT. 1997. The emerging market for long-term nicotine maintenance. JAMA 278:1087-92
94. Wennike P, Danielsson T, Landfeldt B, Westin A, Tønnesen P. 2003. Smoking reduction promotes smoking cessation: results from a double-blind, randomized, placebo-controlled trial of nicotine gum with a 2-year follow-up. Addiction 98:1395-402
95. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. 2001. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology 153:225-30
96. Westman EC, Behm FM, Rose JE. 1996. Airway sensory replacement as a treatment for smoking cessation. Drug Dev. Res. 38:257-62
97. Westman EC, Behm FM, Rose JE. 1996. Dissociating the nicotine and airway sensory effects of smoking. Pharmacol. Biochem. Behav. 53:309-15
98. Deleted in press
99. Yudkin PL, Jones L, Lancaster T, Fowler GH. 1996. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blinded, placebo-controlled trial. Br. J. Gen. Pract. 46:145-48
100. Zhu SH, Melcer T, Sun J, Rosbrook B, Pierce JP. 2000. Smoking cessation with and without assistance: a population-based analysis. Am. J. Prev. Med. 18:305-11